LAMP5 and acute lymphoblastic leukemia: In our validation analyses, SKIDA1 was associated with a higher sensitivity (0.875 vs. CSPG4 = 0.625) and specificity (0.734 vs. CSPG4 = 0.573) in AML, while LAMP5 had greater performance in B-ALL (sensitivity = 0.833 vs. CSPG4 = 0.417; specificity = 0.820 vs. CSPG4 = 0.870) if the overall acute leukemia threshold was used.